HYPE: Forget probiotics: dead bacteria are better for your gut.
But what does the evidence actually show?
Certain inactivated bacterial preparations have evidence for particular benefits, including an IBS trial. That does not establish that postbiotics as a category work better than probiotics, or that any product labelled dead bacteria improves gut health.
Claim assessed: Superiority of postbiotics over probiotics for gut health, while separately assessing evidence for a specific heat-inactivated preparation in IBS.
First, what counts as a postbiotic?
The ISAPP consensus defines postbiotics as preparations containing inanimate microorganisms or their components with a demonstrated benefit to the host. In plain English, the organisms need not be alive, but a benefit still needs to be established. A dead bacterial product does not qualify as useful simply because it is dead. [1]
Probiotics involve live microorganisms given in adequate amounts for a health benefit. Prebiotics are substrates used by host microorganisms that confer a benefit. These categories describe different interventions; they are not a ladder from old technology to a universally better new one. Pure microbial metabolites alone are not postbiotics under the ISAPP definition. [1]
Why inactivated bacteria might still help
Living and multiplying in the gut is not the only possible route to an effect. Cell components can interact with the host, and inactivation may offer manufacturing or storage advantages. However, the strain and inactivation process can alter what is delivered. Stability on a shelf is a practical property, not proof of improved symptoms. [1]
An actual IBS trial provides a useful example
A double-blind trial randomly assigned 443 adults with IBS to heat-inactivated Bifidobacterium bifidum MIMBb75 or placebo for eight weeks. The combined endpoint required improvement in abdominal pain and adequate overall symptom relief during at least four of the eight treatment weeks. About 34% met that endpoint with the preparation versus 19% with placebo. [2]
That is an absolute difference of roughly 15 percentage points in this trial. It supports benefit for this preparation and outcome, while most treated participants still did not meet the combined endpoint. The study was funded by Synformulas, a relevant commercial connection to consider alongside its randomised design. [2]
Why it does not prove postbiotics beat probiotics
The comparator was placebo, not a live probiotic. A favourable placebo-controlled result cannot establish superiority over a treatment that was not compared. Different trials also recruit different patients and use different endpoints, so comparing percentages from unrelated products would be unreliable. [2]
Probiotic research already shows why specificity matters: the organism, strain, formulation, dose and condition can change results. Postbiotics do not escape that requirement. The more useful question is whether the exact preparation has relevant human evidence for the symptom being targeted. [1]
What the newer mechanistic research adds—and leaves open
A 2026 paper compared viable and heat-inactivated MIMBb75 in a Caco-2 intestinal-cell model. Both showed adhesion and barrier-related effects. This offers a possible explanation worth exploring; it is not a new clinical trial showing fewer symptoms or superiority in people. Cell-barrier measurements cannot substitute for patient outcomes. [3]
The clinical evidence also needs replication, longer follow-up and relevant head-to-head trials. Results in adults with diagnosed IBS cannot automatically be assigned to healthy people seeking a general microbiome upgrade.
What this means for you
If considering a product, check the exact strain or preparation and whether a human trial tested it for your intended purpose. A large number on the label, the word postbiotic or a claim about shelf stability does not answer that question.
Persistent digestive symptoms deserve appropriate assessment rather than an assumed need to reset bacteria. There is no need to replace a useful, clinically discussed approach merely because a different biotic category is being marketed as the future. Food habits and targeted treatment remain separate decisions.
Not being alive does not rule out a benefit. It does not establish superiority either.
Research & Sources
Check the evidence yourself. Access limitations and indirect evidence are identified below.
1. Salminen et al. (2021). ISAPP consensus statement on the definition and scope of postbiotics.
Scientific consensus on definitions and evidence requirements.
Read the original source ↗2. Andresen et al. (2020). Heat-inactivated Bifidobacterium bifidum MIMBb75 in irritable bowel syndrome.
Multicentre, randomised, double-blind placebo-controlled trial; published abstract and publisher results.
Read the original source ↗3. Storr and Gschwender (2026). Viable and Heat-Inactivated Bifidobacterium bifidum MIMBb75 Protect the Intestinal Barrier.
Caco-2 cell model; mechanistic evidence, not a human symptom trial.
Read the original source ↗Evidence reviewed: October 2026
Targeted editorial review of sources available on 24 October 2026, not an exhaustive systematic review. Evidence vs Hype provides education, not individual medical diagnosis or treatment. Original AI-generated artwork is illustrative and does not show a study result. No commercial product was selected or endorsed.